EUVIMEDEUVIMED entdecken
Kohortenstudie

A multi‐omics risk score enables early and personalized screening for type 2 diabetes: A population‐based cohort study

Fan Bu iD, Chen Fang iD, Xiao Zheng, Xiu-Juan Yu, Shan-Juan Yuan, Chao-Jie Liu, Zi-Tong Song, Yue-Ping Shen, Lei Zhang, Yu-Fang Pei iD

Diabetic Medicine · 2026-10 · 43 (10)

DOI: 10.1111/dme.70323 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetic Medicine, online erschienen am 11.04.2026. Verfasst von Fan Bu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to develop a multi‐omics model to predict type 2 diabetes onset using multi‐omics data, beyond established clinical and genetic factors.

Methods

In the UK Biobank cohort ( N = 21,312,893 incident type 2 diabetes cases), Ridge Cox regression models were constructed based on clinical factors defined by the Finnish Diabetes Risk Score (CliS), plasma metabolomics (MetS), proteomics (ProS) and polygenic risk score (PRS). Model performance was evaluated by C‐index and net reclassification improvement (NRI). Clinical utility was assessed through net benefit, risk stratification and screening initiation ages. Independent validation of protein markers was performed in the Liyang Cohort ( N = 10,056).

Results

The ProS was the top‐performing single‐omics predictor (C‐index: 0.80). ComS (Combined risk score) achieved the highest discriminative ability (C‐index: 0.84), significantly outperforming the CliS (C‐index: 0.76, NRI: 0.328, p < 0.001). ComS reclassified 73 additional type 2 diabetes cases per 1000 participants not receiving intervention, without increasing false positives. Kaplan–Meier analysis confirmed superior risk stratification of ComS (Log‐rank p < 0.0001). Critically, both MetS and ProS identified high‐risk individuals missed by the conventional CliS. Screening initiation before age 40 was warranted for individuals in the top risk quintile of MetS, ProS, or ComS. In the Liyang Cohort, plasma FGF23 levels were significantly elevated in type 2 diabetes cases ( p < 0.05), corroborating its role as a key proteomic contributor to risk prediction.

Conclusion

The combined multi‐omics model enables more precise, earlier type 2 diabetes risk stratification, supporting personalized screening strategies years before clinical onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansFemaleMultiomicsMaleMiddle AgedProteomicsRisk AssessmentGenetic Risk ScoreMetabolomicsCohort StudiesUK BiobankRisk FactorsUnited KingdomAgedMass ScreeningEarly DiagnosisPrecision Medicine

Stichwörter der Autor:innen

multi‐omicspredictionrisk stratificationtype 2 diabetes

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Moe Key Laboratory of Geriatric Diseases and Immunology, Suz…
  • Department of Clinical Nutrition & Department of Endocrinology, Second Affiliated Hospital of Soochow University, Jiangsu, People's Republic of China.
  • Center for Genetic Epidemiology and Genomics, School of Public Health, Suzhou Medical College of Soochow University, Jiangsu, People's Republic of China.

ORCID-Profile: Fan Bu, Chen Fang, Yu-Fang Pei

Förderung

  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • National Natural Science Foundation of China

Zitieren

APA

Bu, F., Fang, C., Zheng, X., Yu, X. J., Yuan, S. J., Liu, C. J., Song, Z. T., Shen, Y. P., Zhang, L., & Pei, Y. F. (2026). A multi‐omics risk score enables early and personalized screening for type 2 diabetes: A population‐based cohort study. Diabetic Medicine, 43(10). https://doi.org/10.1111/dme.70323

Vancouver

Bu F, Fang C, Zheng X, Yu XJ, Yuan SJ, Liu CJ, et al. A multi‐omics risk score enables early and personalized screening for type 2 diabetes: A population‐based cohort study. Diabetic Medicine. 2026;43(10). doi:10.1111/dme.70323

BibTeX
@article{Bu2026,
  author = {Bu, Fan and Fang, Chen and Zheng, Xiao and Yu, Xiu-Juan and Yuan, Shan-Juan and Liu, Chao-Jie and Song, Zi-Tong and Shen, Yue-Ping and Zhang, Lei and Pei, Yu-Fang},
  title = {A multi‐omics risk score enables early and personalized screening for type 2 diabetes: A population‐based cohort study},
  journal = {Diabetic Medicine},
  year = {2026},
  volume = {43},
  number = {10},
  doi = {10.1111/dme.70323}
}
Kostenlos starten →